AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

Journal of Assisted Reproduction and Genetics

Volumn 31, Issue 10, 2014, Pages 1295-1301

  Pastore, Lisa M ^a   McMurry, Timothy L ^b   Williams, Christopher D ^c   Baker, Valerie L ^d   Young, Steven L ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c Reproductive Medicine and Surgery Center of Virginia   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Anti mullerian hormone; Diminished ovarian reserve; Female infertility; FMR1; Ovarian reserve; Primary ovarian insufficiency; Statistical modeling

Indexed keywords

CLOMIFENE CITRATE; FOLLITROPIN; FRAGILE X MENTAL RETARDATION PROTEIN; MUELLERIAN INHIBITING FACTOR; FMR1 PROTEIN, HUMAN;

ALLELE; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FRAGILE X SYNDROME; GENOTYPE; HORMONE BLOOD LEVEL; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; OUTCOME VARIABLE; OVARIAN RESERVE; PREMATURE OVARIAN FAILURE; ADULT; BIOSYNTHESIS; BLOOD; GENETICS; METABOLISM; OOCYTE; OVARY; TRINUCLEOTIDE REPEAT;

ADULT; ANTI-MULLERIAN HORMONE; FEMALE; FOLLICLE STIMULATING HORMONE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENOTYPE; HUMANS; OOCYTES; OVARIAN RESERVE; OVARY; PRIMARY OVARIAN INSUFFICIENCY; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84918789985     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-014-0276-2     Document Type: Article

References (34)

1. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IAJ, de Vet A, Themmen APN, et al. Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. J Clin Endocrin Metab. 2011;96(8):2532–9. doi:10.1210/jc.2010-2776.
2. Choe SA, Kim KC, Lee JY, Kim CH, Hwang D, Jee BC. The relationship between the number of CGG repeats and serum level of anti-Mullerian hormone in women without FMR1 premutation. Eur J Obstet Gynecol Reprod Biol. 2013. doi:10.1016/j.ejogrb.2013.05.002.
3. De Geyter C, M’Rabet N, De Geyter J, Zurcher S, Moffat R, Bosch N, et al. Similar prevalence of expanded CGG repeat lengths in the fragile X mental retardation I gene among infertile women and among women with proven fertility: a prospective study. Genetics in Med. 2013. doi:10.1038/gim.2013.146.
4. Friese C, Becker G, Nachtigall RD. Rethinking the biological clock: eleventh-hour moms, miracle moms and meanings of age-related infertility. Social Sci Med. 2006;63(6):1550–60.
5. Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril. 2009;91(5):1700–6. doi:10.1016/j.fertnstert.2008.01.098.
6. Gleicher N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: A new infertility test? Acta Obstet Gynecol Scand. 2009;88(9):1024–30. doi:10.1080/00016340903171058.
7. Hadlow N, Longhurst K, McClements A, Natalwala J, Brown SJ, Matson PL. Variation in antimüllerian hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. Fertil Steril. 2013;99(6). doi:10.1016/j.bbr.2011.03.031
8. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170–5. doi:10.1016/j.fertnstert.2010.04.006.
9. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrin Metab. 2006;91(10):4057–63.
10. Iino K, Tarakida A, Abe K, Taniguchi R, Higuchi T, Takahashi I, et al. Role of antimullerian hormone as a biomarker of the menopausal transition. Menopause. 2013;20(2):218–22. doi:10.1097/gme.0b013e3182611574.
11. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril.99(5):1305–10
12. Karimov CB, Moragianni VA, Cronister A, Srouji S, Petrozza J, Racowsky C, et al. Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum Reprod. 2011;26(8):2077–83.
13. Kline JK, Kinney AM, Levin B, Brown SA, Hadd AG, Warburton D. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause. 2014. doi:10.1097/gme.0000000000000139
14. Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, et al. High frequency of discordance between antimullerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril. 2012;98(4):1037–42.
15. Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott Jr RT. Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril. 2001;76(4):666–9.
16. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Repro Biomed Online. 2011;23(4):411–20.
17. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil Steril. 2011;95(2):736–41. doi:10.1016/j.fertnstert.2010.08.022. e3.
18. Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G et al. The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol.27(8):587–92
19. Pastore LM, Young SL, Baker VM, Karns LB, Williams CD, Silverman LM. Elevated Prevalence of 35–44 FMR1 Trinucleotide Repeats in Women with Diminished Ovarian Reserve. Reprod Sci. 2012;19(11):1226–31.
20. Peprah E. Fragile X Syndrome: The FMR1 CGG Repeat Distribution Among World Populations. Ann Hum Genet. 2011. doi:10.1111/j.1469-1809.2011.00694.x.
21. Rohr J, Allen EG, Charen K, Giles J, He W, Dominguez C, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod. 2008;23(5):1220–5. doi:10.1093/humrep/den050.
22. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27(2):594–608. doi:10.1093/humrep/der391.
23. Scott Jr RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63(1):1–11.
24. Scriver J, Baker V, Young S, Behr B, Pastore L. Inter-laboratory validation of the measurement of follicle stimulating hormone (FSH) after various lengths of frozen storage. Reprod Biology Endocrin. 2010;8(1):145.
25. Sharara FI, Scott JRT, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol. 1998;179(3):804–12.
26. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97:189–94.
27. Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril. 2010;94(4):1482–6. doi:10.1016/j.fertnstert.2009.07.1674.
28. Spath MA, Feuth TB, Allen EG, Smits AP, Yntema HG, van Kessel AG, et al. Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Hum Reprod. 2011;26(8):2185–91. doi:10.1093/humrep/der146.
29. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril.90(2):395–400
30. Streuli I, Fraisse T, Ibecheole V, Moix I, Morris MA, de Ziegler D. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency. Fertil Steril. 2009;92(2):464–70.
31. Taieb J, Olivennes F, Birr AS, Benattar C, Righini C, Frydman R, et al. Comparison of day 3 FSH serum values as determined by six different immunoassays. Hum Reprod. 2002;17(4):926–8.
32. Therneau T. Survival: A Package for Survival Analysis in S. R package 2.37-2 edition ed2012.
33. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–6. doi:10.1016/j.mce.2004.09.008.
34. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77–83.